Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Sell
35
AKTX Quote, Financials, Valuation and Earnings
Last price:
$1.21
Seasonality move
:
-7.69%
Day range:
$1.15 - $1.22
52-week range:
$0.90 - $4.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.34x
Volume:
41.4K
Avg. volume:
73.4K
1-year change:
-58.39%
Market cap:
$30.1M
Revenue:
--
EPS (TTM):
-$2.75
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Akari Therapeutics PLC has 6484.36% upside to fair value with a price target of -- per share.
AKTX vs. S&P 500
-
Over the past 5 trading days, Akari Therapeutics PLC has overperformed the S&P 500 by 2.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Akari Therapeutics PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Akari Therapeutics PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Akari Therapeutics PLC reported revenues of --.
Earnings Growth
-
Akari Therapeutics PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Akari Therapeutics PLC reported earnings per share of -$0.24.
Enterprise value:
28.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.94x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -$17.5M | -$18.5M | -$2.5M | -$1.9M | |
| EBITDA | -- | -$17.3M | -$27.2M | -$2.9M | -$2.8M | |
| Diluted EPS | -- | -$3.01 | -$2.75 | -$0.57 | -$0.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.7M | $14.7M | -- | -- | $2.7M | |
| Total Assets | $13.7M | $14.7M | -- | -- | $2.7M | |
| Current Liabilities | $8.8M | $3.4M | -- | -- | $9.4M | |
| Total Liabilities | $8.8M | $3.4M | -- | -- | $9.4M | |
| Total Equity | $4.9M | $11.4M | -- | -- | -$6.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$20.6M | -$14.8M | -$2.4M | -$1.5M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | $3.5M | $12.4M | -- | -$443K | |
| Free Cash Flow | -- | -$20.6M | -$14.8M | -$2.4M | -$1.5M | |
AKTX
Sector
Market Cap
$30.1M
$47.5M
Price % of 52-Week High
27.61%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-58.39%
-34.04%
Beta (5-Year)
0.789
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$1.25
200-day SMA
Sell
Level
$2.36
Bollinger Bands (100)
Sell
Level
1.36 - 3.26
Chaikin Money Flow
Sell
Level
-3.4M
20-day SMA
Buy
Level
$1.09
Relative Strength Index (RSI14)
Sell
Level
47.91
ADX Line
Buy
Level
46.2
Williams %R
Neutral
Level
-47.1154
50-day SMA
Sell
Level
$1.52
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
118.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Stock Forecast FAQ
In the current month, AKTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AKTX average analyst price target in the past 3 months is --.
-
Where Will Akari Therapeutics PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Akari Therapeutics PLC share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Akari Therapeutics PLC?
Analysts are divided on their view about Akari Therapeutics PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Akari Therapeutics PLC is a Sell and believe this share price will drop from its current level to --.
-
What Is Akari Therapeutics PLC's Price Target?
The price target for Akari Therapeutics PLC over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AKTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Akari Therapeutics PLC is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of AKTX?
You can purchase shares of Akari Therapeutics PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Akari Therapeutics PLC shares.
-
What Is The Akari Therapeutics PLC Share Price Today?
Akari Therapeutics PLC was last trading at $1.21 per share. This represents the most recent stock quote for Akari Therapeutics PLC. Yesterday, Akari Therapeutics PLC closed at $1.22 per share.
-
How To Buy Akari Therapeutics PLC Stock Online?
In order to purchase Akari Therapeutics PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
